Clinical trials remain the cornerstone of oncology drug development, providing the evidentiary basis for regulatory approval and clinical adoption. In advanced non–small cell lung cancer (NSCLC), a rapidly evolving therapeutic landscape—including targeted therapies and immunotherapies—has been shaped almost entirely by trial-driven evidence. However, alongside these successes, a growing body of literature and professional discourse highlights important limitations within the current clinical trial framework. These concerns do not undermine the necessity of trials but rather emphasize the need for critical evaluation and iterative improvement.

This article examines key systemic, methodological, and practical challenges in cancer clinical trials, with particular attention to advanced NSCLC.

1. Patient Selection Bias and Limited Generalizability

One of the most widely recognized limitations of oncology trials is restrictive eligibility criteria. Advanced NSCLC trials frequently exclude patients with poor performance status (e.g., ECOG ≥2), significant comorbidities, brain metastases, or prior malignancies. While such criteria are intended to reduce confounding variables and enhance internal validity, they significantly limit external applicability.

Studies have shown that only a small fraction of real-world NSCLC patients would meet eligibility criteria for landmark trials. This creates a disconnect between trial populations and routine clinical practice, where patients are older, frailer, and more heterogeneous. For example, patients with organ dysfunction or autoimmune disease are often excluded from immunotherapy trials, despite representing a meaningful proportion of the real-world population.

The consequence is that clinicians must extrapolate efficacy and safety data beyond the populations in which they were tested. This raises concerns about both overestimation of benefit and under-recognition of toxicity in broader patient groups.

2. Trial Timelines and Delayed Access to Therapies

The timeline from early-phase development to regulatory approval in oncology can span a decade or more. In advanced NSCLC, where median survival remains limited despite therapeutic advances, such delays can have significant implications for patient outcomes.

While expedited pathways (e.g., accelerated approval, breakthrough designation) have improved timelines for some targeted therapies, delays persist due to complex trial designs, slow accrual, and regulatory requirements. Additionally, confirmatory phase III trials required after accelerated approvals may take years to complete, during which time clinical uncertainty remains.

Another important issue is the lag between trial completion and real-world accessibility. Even after regulatory approval, disparities in reimbursement, infrastructure, and healthcare systems can delay patient access—particularly in low- and middle-income settings.

Adaptive trial designs, platform trials (e.g., umbrella and basket trials), and real-world data integration have been proposed as solutions, but their implementation remains inconsistent.

3. Financial Barriers and Accessibility Challenges

The cost of conducting oncology trials has risen substantially, driven by increasing complexity, biomarker testing requirements, and administrative burdens. These costs are often passed along indirectly through healthcare systems, contributing to broader issues of affordability.

For patients, participation in trials may involve significant logistical and financial burdens, including travel, time off work, and out-of-pocket expenses. Although some trials offer reimbursement, this is not universal and may disproportionately affect patients from lower socioeconomic backgrounds.

Geographic disparities further compound these challenges. Advanced NSCLC trials are often concentrated in academic centers, limiting access for patients in rural or underserved regions. This contributes to underrepresentation of certain populations, including ethnic minorities and lower-income groups.

From a system perspective, industry-sponsored trials tend to focus on commercially viable interventions, potentially neglecting less profitable but clinically important research questions.

4. Ethical Considerations: Placebo Use and Equipoise

The use of placebo controls in oncology trials, particularly in advanced disease settings, remains ethically complex. While placebo-controlled designs are scientifically rigorous, their appropriateness depends on the availability of effective standard-of-care treatments.

In advanced NSCLC, where multiple lines of therapy may exist, placebo use is generally limited to add-on designs (e.g., standard therapy plus placebo vs. standard therapy plus investigational agent). However, concerns persist regarding true equipoise, especially when emerging evidence suggests benefit from active treatments.

Crossover designs are often implemented to address ethical concerns, allowing patients in control arms to receive the investigational therapy upon progression. While ethically favorable, crossover can confound overall survival analyses, making it more difficult to interpret long-term benefit.

Balancing methodological rigor with ethical responsibility remains a central challenge in trial design, particularly as therapeutic options expand.

5. Heterogeneity and Biomarker Complexity

Advanced NSCLC is no longer a single disease entity but a collection of molecularly defined subtypes. Trials increasingly rely on biomarker-driven inclusion criteria (e.g., EGFR mutations, ALK rearrangements, PD-L1 expression), which has improved treatment precision but introduced new challenges.

Biomarker heterogeneity—both spatial and temporal—can complicate patient selection and response assessment. Tumor evolution under treatment pressure may lead to resistance mechanisms not captured at baseline. Additionally, variability in testing methods and thresholds (e.g., PD-L1 assays) can affect trial comparability.

Small, biomarker-selected populations also lead to smaller sample sizes, increasing statistical uncertainty and limiting subgroup analyses. While enrichment strategies improve signal detection, they may obscure broader applicability.

6. Dropout Rates and Data Integrity

Attrition is a significant issue in advanced cancer trials. Patients may discontinue participation due to disease progression, toxicity, logistical challenges, or personal choice. High dropout rates can introduce bias, particularly if attrition is non-random.

In advanced NSCLC, where disease progression is common, missing data can complicate endpoint interpretation. Progression-free survival (PFS), a commonly used endpoint, may be affected by inconsistent imaging intervals or early discontinuation.

Furthermore, reliance on surrogate endpoints such as PFS or response rate—while expedient—does not always translate into overall survival or quality-of-life benefits. This has been a point of ongoing debate in regulatory and academic circles.

Efforts to improve data integrity include more robust statistical methods for handling missing data, as well as incorporation of patient-reported outcomes. However, standardization remains a challenge.

7. Regulatory Bottlenecks and Administrative Complexity

Regulatory oversight is essential for ensuring patient safety and scientific validity, but it can also introduce delays and inefficiencies. Multinational trials must navigate varying regulatory requirements, ethics approvals, and data reporting standards.

Administrative burdens—such as extensive documentation, monitoring requirements, and contract negotiations—can slow trial initiation and increase costs. Smaller institutions may lack the infrastructure to participate, further limiting trial diversity.

Recent initiatives aimed at streamlining processes, including centralized ethics review and digital data capture, show promise but are not yet universally adopted.

8. Efficacy vs. Real-World Effectiveness

Perhaps the most critical limitation is the gap between trial efficacy and real-world effectiveness. Clinical trials are conducted under controlled conditions with selected populations, high adherence, and close monitoring. In contrast, real-world practice involves variable adherence, comorbidities, and resource constraints.

Real-world studies in advanced NSCLC have sometimes shown lower response rates and shorter survival compared to pivotal trials. This discrepancy underscores the importance of post-marketing surveillance and real-world evidence generation.

Bridging this gap requires integration of pragmatic trial designs, broader eligibility criteria, and systematic use of real-world data sources such as registries and electronic health records.

Conclusion

Cancer clinical trials, including those in advanced NSCLC, remain indispensable for advancing oncology care. However, their limitations are increasingly recognized and warrant thoughtful consideration. Issues such as restrictive eligibility criteria, prolonged timelines, financial and geographic barriers, ethical complexities, and the gap between trial and real-world outcomes highlight the need for continued evolution in trial design and implementation.

Emerging approaches—including adaptive designs, decentralized trials, and real-world data integration—offer potential pathways forward. For medical professionals, understanding these limitations is essential not only for interpreting trial results but also for advocating improvements that enhance both scientific rigor and patient-centered care.

A balanced perspective—acknowledging both the strengths and shortcomings of clinical trials—will be critical in shaping the next generation of oncology research.